• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 Kv1.3 抑制剂结构类别设计与特性研究。

Design and characterization of a novel structural class of Kv1.3 inhibitors.

机构信息

University of Leuven (KUL), Toxicology and Pharmacology, Campus Gasthuisberg, Onderwijs en Navorsing 2, Herestraat 49, PO Box 922, 3000 Leuven, Belgium.

University of Belgrade, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Vojvode Stepe 450, 11221 Belgrade, Serbia.

出版信息

Bioorg Chem. 2020 May;98:103746. doi: 10.1016/j.bioorg.2020.103746. Epub 2020 Mar 18.

DOI:10.1016/j.bioorg.2020.103746
PMID:32199306
Abstract

The voltage-gated potassium channel K1.3 is involved in multiple autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, diabetes mellitus type 1 and psoriasis. In many auto-immune diseases better treatment options are desired as existing therapies are often ineffective or become less effective over time, for which K1.3 inhibitors arise as promising candidates. In this study, five compounds were selected based on a 3D similarity searching methodology and subsequently screened ex vivo on the K1.3 channel. The screening resulted in two compounds inhibiting the K1.3 channel, of which TVS-12 was the most potent compound, while TVS-06 -although less potent- showed an excellent selectivity for K1.3. For both compounds the mechanism of action was investigated by an electrophysiological characterization on the K1.3 channel and three K1.3 mutants, designed to resemble the pore region of K1.2 channels. Structurally, the presence of a benzene ring and/or an oxane ring seems to cause a better interaction with the K1.3 channel, resulting in a 20-fold higher potency for TVS-12.

摘要

电压门控钾通道 K1.3 参与多种自身免疫性疾病,如多发性硬化症、类风湿性关节炎、1 型糖尿病和银屑病。在许多自身免疫性疾病中,人们希望有更好的治疗选择,因为现有的治疗方法往往无效或随着时间的推移效果降低,而 K1.3 抑制剂作为有前途的候选药物出现。在这项研究中,基于 3D 相似性搜索方法选择了五种化合物,并随后在 K1.3 通道上进行了离体筛选。筛选结果显示两种化合物抑制 K1.3 通道,其中 TVS-12 是最有效的化合物,而 TVS-06 -尽管效力较低-对 K1.3 显示出优异的选择性。对于这两种化合物,通过在 K1.3 通道和三个设计为类似于 K1.2 通道孔区的 K1.3 突变体上进行电生理特性研究,研究了其作用机制。从结构上看,苯环和/或氧杂环丁烷的存在似乎与 K1.3 通道有更好的相互作用,导致 TVS-12 的效力提高了 20 倍。

相似文献

1
Design and characterization of a novel structural class of Kv1.3 inhibitors.新型 Kv1.3 抑制剂结构类别设计与特性研究。
Bioorg Chem. 2020 May;98:103746. doi: 10.1016/j.bioorg.2020.103746. Epub 2020 Mar 18.
2
Methotrexate, a small molecular scaffold targeting Kv1.3 channel extracellular pore region.甲氨蝶呤,一种靶向 Kv1.3 通道细胞外孔区的小分子支架。
Biochem Biophys Res Commun. 2020 Nov 5;532(2):265-270. doi: 10.1016/j.bbrc.2020.08.050. Epub 2020 Aug 28.
3
Synthesis and biological evaluation of chalcones as inhibitors of the voltage-gated potassium channel Kv1.3.查耳酮作为电压门控钾通道Kv1.3抑制剂的合成及生物学评价
Bioorg Med Chem Lett. 2008 Mar 15;18(6):2055-61. doi: 10.1016/j.bmcl.2008.01.099. Epub 2008 Jan 31.
4
N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.来自海葵的钾通道毒素的N端延伸类似物作为电压门控钾通道Kv1.3的强效和选择性阻滞剂。
FEBS J. 2015 Jun;282(12):2247-59. doi: 10.1111/febs.13294. Epub 2015 Apr 23.
5
Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.电压门控钾通道Kv1.5新型阻滞剂的鉴定、合成及活性
J Med Chem. 2003 Feb 13;46(4):486-98. doi: 10.1021/jm0210461.
6
The voltage-gated potassium channel K1.3 as a therapeutic target for venom-derived peptides.电压门控钾通道 K1.3 作为毒液衍生肽的治疗靶点。
Biochem Pharmacol. 2020 Nov;181:114146. doi: 10.1016/j.bcp.2020.114146. Epub 2020 Jul 10.
7
KcsA-Kv1.x chimeras with complete ligand-binding sites provide improved predictivity for screening selective Kv1.x blockers.具有完整配体结合位点的KcsA-Kv1.x嵌合体为筛选选择性Kv1.x阻滞剂提供了更高的预测性。
J Biol Chem. 2024 Apr;300(4):107155. doi: 10.1016/j.jbc.2024.107155. Epub 2024 Mar 11.
8
A new Kaliotoxin selective towards Kv1.3 and Kv1.2 but not Kv1.1 channels expressed in oocytes.一种对卵母细胞中表达的Kv1.3和Kv1.2通道具有选择性,但对Kv1.1通道无选择性的新型卡利毒素。
Biochem Biophys Res Commun. 2008 Nov 21;376(3):525-30. doi: 10.1016/j.bbrc.2008.09.033. Epub 2008 Sep 18.
9
Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.一种为Kv1.3通道设计的强效肽抑制剂的结构基础,Kv1.3通道是自身免疫性疾病的治疗靶点。
J Biol Chem. 2008 Jul 4;283(27):19058-65. doi: 10.1074/jbc.M802054200. Epub 2008 May 14.
10
Novel Kv1.3 blockers for immunosuppression: WO2012155199.新型 Kv1.3 通道阻滞剂的免疫抑制作用:WO2012155199。
Expert Opin Ther Pat. 2013 Nov;23(11):1511-6. doi: 10.1517/13543776.2013.831072. Epub 2013 Aug 23.

引用本文的文献

1
High throughput clone screening on overexpressed hERG1 and Kv1.3 potassium channels using ion channel reader (ICR) label free technology.使用离子通道读数器(ICR)无标记技术对过表达的人乙醚相关基因1(hERG1)和钾通道蛋白1.3(Kv1.3)钾通道进行高通量克隆筛选。
Heliyon. 2023 Sep 19;9(10):e20112. doi: 10.1016/j.heliyon.2023.e20112. eCollection 2023 Oct.
2
Design of New Potent and Selective Thiophene-Based K1.3 Inhibitors and Their Potential for Anticancer Activity.新型强效选择性噻吩基K1.3抑制剂的设计及其抗癌活性潜力
Cancers (Basel). 2022 May 24;14(11):2595. doi: 10.3390/cancers14112595.
3
Review on Biological Characteristics of Kv1.3 and Its Role in Liver Diseases.
Kv1.3的生物学特性及其在肝脏疾病中的作用综述
Front Pharmacol. 2021 May 21;12:652508. doi: 10.3389/fphar.2021.652508. eCollection 2021.
4
Discovery of K 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.K1.3 离子通道抑制剂的发现:药物化学方法与挑战。
Med Res Rev. 2021 Jul;41(4):2423-2473. doi: 10.1002/med.21800. Epub 2021 May 1.
5
Tuning Scorpion Toxin Selectivity: Switching From K1.1 to K1.3.调整蝎毒素的选择性:从K1.1转换至K1.3
Front Pharmacol. 2020 Jul 7;11:1010. doi: 10.3389/fphar.2020.01010. eCollection 2020.